灵康药业(603669) - 2024 Q3 - 季度财报(更正)

Financial Performance - The company's operating revenue for Q3 2024 was ¥89,552,626.84, representing a 137.26% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[5]. - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase from ¥150,665,541.41 in the same period of 2023, representing a growth of approximately 53.3%[33]. - The net loss for the first three quarters of 2024 was ¥46,889,888.23, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023, reflecting a reduction of approximately 51.5%[36]. - The total comprehensive loss for the first three quarters of 2024 was ¥46,889,888.23, compared to a loss of ¥96,582,500.85 in 2023, reflecting a reduction of approximately 51.5%[39]. Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥64,056,674.63[7]. - In the first three quarters of 2024, the cash inflow from operating activities was CNY 273,547,756.34, compared to CNY 260,896,973.39 in the same period of 2023, representing an increase of approximately 4.3%[40]. - The net cash outflow from operating activities in the first three quarters of 2024 was CNY -64,056,674.63, worsening from CNY -21,150,724.69 in the first three quarters of 2023[44]. - The total cash outflow from operating activities was CNY 337,604,430.97 in the first three quarters of 2024, compared to CNY 282,047,698.08 in the same period of 2023, reflecting an increase of approximately 19.7%[44]. - The ending cash and cash equivalents balance as of the end of the third quarter of 2024 was CNY 121,210,711.78, down from CNY 448,275,862.91 at the end of the same period in 2023, a decrease of approximately 73.0%[46]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% from the end of the previous year[8]. - The total liabilities decreased to ¥710,481,179.23 from ¥743,026,871.85, a decline of about 4%[28]. - The total current assets decreased to ¥495,170,740.50 from ¥881,533,254.03, a reduction of about 44%[28]. - The company's total liabilities decreased to ¥349,929,587.69 in 2024 from ¥693,517,978.39 in 2023, a reduction of approximately 49.6%[33]. - Long-term equity investments decreased to ¥28,760,795.15 from ¥40,874,881.63, a decline of about 30%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,589[18]. - The largest shareholder, Lingkang Holdings Group Co., Ltd., holds 339,652,800 shares, accounting for 47.09% of total shares[18]. - The company repurchased 17,701,793 shares, representing 2.45% of total shares[24]. - There are no known related party relationships among the top shareholders, except for siblings among some of them[22]. Operational Highlights - The company reported a significant increase in its core product lines, with a 117.21% growth in existing formulations and a 100% growth in pharmaceutical distribution compared to the same period last year[13]. - The company has been focusing on cost control and maximizing production capacity to improve profitability[13]. - The company plans to continue expanding its market presence and product offerings in the upcoming quarters[13]. Earnings and Expenses - The basic earnings per share for Q3 2024 was -¥0.01, with a year-to-date figure of -¥0.07[8]. - Research and development expenses decreased to ¥14,987,666.90 in 2024 from ¥21,226,696.58 in 2023, showing a decline of about 29.5%[33]. - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.07, an improvement from -¥0.13 in the same period of 2023[39]. - The company recorded a financial expense of -¥19,037,217.99 in 2024, a notable improvement from a financial expense of ¥430,723.86 in 2023[33]. - The company reported a financial asset impairment loss of ¥46,298.03 in 2024, compared to a loss of ¥1,989,226.07 in 2023, indicating a significant improvement[36].